Zimmer Biomet Holdings, Inc. filings document a public medical technology company with common stock listed under ZBH and several registered notes listed on the New York Stock Exchange. Recent 8-K reports cover quarterly and annual operating results, updated financial guidance, executive officer departures and interim finance leadership, debt securities, and completed acquisition activity.
The company's proxy and event filings disclose board and executive compensation matters, governance votes, Section 12(b) securities, material agreements, senior unsecured debt obligations, and exhibits tied to earnings releases. These records frame Zimmer Biomet's capital structure, leadership changes, shareholder governance and financial reporting for its orthopedic and musculoskeletal technology business.
Zimmer Biomet Holdings' Executive VP and CFO Suketu Upadhyay reported equity award activity involving restricted stock units and common shares. On February 25, 2026, he exercised 6,364 restricted stock units, converting them into 6,364 shares of common stock at a stated price of $0.0000 per share. Following this conversion, his direct holdings increased to 64,117 shares of common stock and 12,726 restricted stock units. On the same date, 2,832 common shares at $99.51 per share were withheld by the company to satisfy tax withholding obligations linked to the RSU vesting, rather than an open-market sale.
Zimmer Biomet Holdings Chairman, President and CEO Ivan Tornos reported equity award activity involving restricted stock units and common shares of ZBH. He exercised or converted 19,090 restricted stock units into 19,090 shares of common stock at a price of $0.0000 per share. To cover tax withholding on the RSU vesting, 10,557 common shares were withheld by the company at a price of $99.5100 per share, as described in the footnotes. Following these transactions on February 25, 2026, his directly held common stock position was 67,682 shares, and 38,179 restricted stock units remained outstanding, with one-third vesting on February 25, 2026 and the balance vesting in equal installments on February 25, 2027 and February 25, 2028.
Zimmer Biomet Holdings officer Paul A. Stellato reported equity compensation activity involving restricted stock units (RSUs) and common shares. On February 25, 2026, 820 RSUs were exercised and converted into 820 shares of common stock at a stated price of $0.0000 per share.
On the same date, 402 common shares were withheld at $99.5100 per share to cover tax withholding obligations related to the RSU vesting, as described in the footnotes. One-third of the RSUs vested on February 25, 2026, with the remaining RSUs scheduled to vest one-half on each of February 25, 2027 and February 25, 2028.
Following these transactions, Stellato directly held 1,638 RSUs and 4,527 shares of common stock. The disposition was for tax withholding rather than an open-market sale.
Noor Jehanzeb reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. reported that officer Noor Jehanzeb received a grant of 10,076 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of company common stock. The award vests annually over three years in one-third increments starting on February 20, 2027.
ZIMMER BIOMET HOLDINGS, INC. officer Chad F. Phipps reported equity compensation and related share movements. On February 20, 2026, 2,246 restricted stock units were exercised into 2,246 shares of common stock at a price of $0.00 per share.
He was also granted 9,818 new restricted stock units, each representing a right to receive one common share, vesting annually over three years in one‑third installments starting February 20, 2027. To satisfy tax withholding on the RSU vesting, 942 common shares were disposed of at $98.62 per share through company share withholding, leaving him with 62,137 directly held common shares.
Thornal Kevin R reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings, Inc. reported that executive Kevin R. Thornal, Group President–Global Business, received a grant of 27,385 restricted stock units (RSUs) on February 20, 2026. Each RSU represents a contingent right to receive one share of common stock and vests in three equal annual installments starting February 20, 2027.
Zimmer Biomet Holdings executive Yi Sang reported equity awards and conversions, increasing his direct holdings through stock-based compensation. He acquired 2,382 shares of common stock on February 20, 2026 via exercise or conversion of restricted stock units (RSUs) at $0.00 per share, bringing his direct common stock ownership to 20,052 shares.
On the same date, he also acquired 2,382 RSUs through an exercise or conversion and received a new grant of 9,043 RSUs. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock and vests annually over three years in one-third increments starting on February 20, 2027.
Zimmer Biomet Group Pres, EMEA Wilfred Van Zuilen reported equity compensation activity. On February 20, 2026, 2,451 restricted stock units vested into the same number of common shares, and 638 shares were withheld to cover tax obligations. He also received a new award of 10,334 restricted stock units that vest annually over three years starting February 20, 2027. After these transactions, he directly holds 12,784 restricted stock units and 23,455 shares of common stock.
Zimmer Biomet Holdings, Inc. senior vice president and chief human resources officer Lori Winkler reported equity compensation activity involving restricted stock units (RSUs) and common stock. On February 20, 2026, 1,845 RSUs were converted into 1,845 shares of common stock, and she received a new grant of 7,880 RSUs. According to the disclosure, each RSU represents a contingent right to receive one share of company common stock, and the new grant vests annually over three years in one-third increments starting February 20, 2027. The filing also shows 683 shares of common stock were withheld by the company at $98.62 per share to satisfy tax withholding obligations related to the RSU vesting.
Zimmer Biomet Holdings, Inc. reported that VP, Controller and Chief Accounting Officer Paul A. Stellato received new equity awards and related share movements. On February 20, 2026, he acquired 701 restricted stock units (RSUs) through an exercise or conversion and received additional RSU grants of 2,842 and 4,651 units at no cost. Each RSU represents a contingent right to one share of common stock, with one grant vesting annually over three years starting February 20, 2027, and the other vesting in full on February 20, 2028.
The 701 RSUs were converted into 701 shares of common stock, increasing his direct common stock holdings before tax withholding. To cover tax obligations on the RSU vesting, 362 common shares were withheld by the company at a price of $98.62 per share, leaving him with 4,109 common shares directly held, which includes 60 shares previously acquired under the Employee Stock Purchase Plan.